Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient c

Tweet Author

Tweet Content

Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient care. Sponsored By: Boehringer Ingelheim https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/5wD1K7J1Gq

Links

ILD Treatment and Guidelines | RheumNow https://buff.ly/w9qmEr7

Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif co

Tweet Author

RheumNow

Tweet Content

Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif correlation w/ US synovitis. Baseline calprotectin, S100A12, IL-6, IL-17A, IL-23, CXCL10 were high. Calprotectin, S100A12, IL-6 decreased w/ Rx (p < 0.05).

Controversies in ILD

17 September 2025

SARD-ILD: Significant diagnostic and treatment delays

Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which were published in May, recommend universal CT chest screening for all asymptomatic patients with RA, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren’s disease.

QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with

Tweet Author

RheumNow

Tweet Content

QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/HLnX5WbbTw https://t.co/SZeI4bqSAm

Links

QD Clinic: Beyond the Numbers in Newly Diagnosed ILD | RheumNow https://buff.ly/Br9q5Se

How to assess ILD in your patients? Have a high index of suspicion in your patients with connective tissue disease (esp

Tweet Author

RheumNow

Tweet Content

How to assess ILD in your patients? Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis. All patients with CTD may develop ILD but it is more common (% of patients with https://t.co/UXdvPJCqDi

August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort a

Tweet Author

RheumNow

Tweet Content

August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort and expense of maintaining the committee “is no longer justified.” The committee last met on 5/6/21 to review avacopan - that was subsequently approved. REALLY? https://t.co/w3Z6TszeWZ

Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor to the overdose

Tweet Author

RheumNow

Tweet Content

Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor to the overdose crisis; they are over 20 times more potent than fentanyl. Nitazenes are an illegal Schedule I drug that are rapidly spreading in the illicit drug market

Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It has shown

Tweet Author

RheumNow

Tweet Content

Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in rheumatoid arthritis and psoriatic arthritis and is now being increasingly adopted not only in SLE research https://t.co/PfnG0AeJsH

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on

Tweet Author

RheumNow

Tweet Content

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month. https://t.co/T68Cprogm3

Topics

Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient c

Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif co

Controversies in ILD

QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with

How to assess ILD in your patients? Have a high index of suspicion in your patients with connective tissue disease (esp

August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort a

Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor to the overdose

Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It has shown

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on

Do you get our email newsletter?